secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-107013
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026
--------------------------------------------------------------------------------

- Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).
- Net loss $12.9M ($0.49/share) vs $13.1M ($0.57/share) in Q3 2024; per-share loss improved.
- U.S. active implanting centers reached 250, up 20% year-over-year.
- CMS finalized Category I CPT codes for Barostim, improving patient access and removing adoption barriers.
- FY2025 guidance: revenue $55.6M-$56.6M (narrowed from $55M-$57M), gross margin 85%-86% (raised from 83%-84%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/0001104659-25-107013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465925107013/tm2530302d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer